Skip to main
BCPC

Balchem (BCPC) Stock Forecast & Price Target

Balchem (BCPC) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Balchem Corp is forecasting substantial earnings growth, with anticipated GAAP earnings of $4.73 per diluted share for 2025 and $5.17 per diluted share for 2026, reflecting increased confidence in the Human Nutrition and Health segment's strength. The company has demonstrated operational efficiency and revenue growth, reporting a revenue increase of 9.8% year-over-year, alongside improving gross and net margins, which rose to 35.6%. Furthermore, with the potential to become debt-free by the end of the year and the ability to pursue accretive M&A transactions, Balchem's strong balance sheet supports a positive financial outlook.

Bears say

Balchem Corp's financial outlook has been downgraded, with projected earnings for full-year 2026 revised down to $5.10 per diluted share from a previous estimate of $5.17, contributing to a decline in the price-to-earnings (P/E) multiple from 39.6x to 37.9x. The company is facing significant risks, including slower growth in its core businesses, inflationary pressures, and potential setbacks related to new product launches and regulatory approvals from partners. Additionally, revenue performance has lagged, as evidenced by the Human Nutrition and Health segment reporting revenue of $166.1 million in 4Q25, falling short of the forecasted $170 million, indicating potential ongoing challenges in meeting market expectations.

Balchem (BCPC) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Balchem (BCPC) Forecast

Analysts have given Balchem (BCPC) a Buy based on their latest research and market trends.

According to 2 analysts, Balchem (BCPC) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $176, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $176, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Balchem (BCPC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.